Organovo Stock Price, News & Analysis (NASDAQ:ONVO) $1.18 0.00 (0.00%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$1.16▼$1.2050-Day Range$1.05▼$1.8452-Week Range$1.00▼$3.40Volume28,024 shsAverage Volume76,325 shsMarket Capitalization$10.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Organovo MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish5.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingSelling Shares$31,763 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.75) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.23 out of 5 starsMedical Sector921st out of 949 stocksBiological Products, Except Diagnostic Industry158th out of 160 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Organovo. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.09% of the outstanding shares of Organovo have been sold short.Short Interest Ratio / Days to CoverOrganovo has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organovo has recently increased by 2.40%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOrganovo does not currently pay a dividend.Dividend GrowthOrganovo does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONVO. Previous Next 3.3 News and Social Media Coverage News SentimentOrganovo has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Organovo this week, compared to 0 articles on an average week.Search Interest15 people have searched for ONVO on MarketBeat in the last 30 days. This is an increase of 650% compared to the previous 30 days.MarketBeat Follows3 people have added Organovo to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Organovo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,763.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Organovo is held by insiders.Percentage Held by InstitutionsOnly 9.14% of the stock of Organovo is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Organovo are expected to decrease in the coming year, from ($1.75) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organovo is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organovo is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrganovo has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Organovo Stock (NASDAQ:ONVO)Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Read More ONVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONVO Stock News HeadlinesNovember 24, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)November 20, 2023 | americanbankingnews.comInsider Selling: Organovo Holdings, Inc. (NASDAQ:ONVO) Director Sells $31,763.34 in StockNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 13, 2023 | msn.comOVNO Continues Developing Breakthrough TreatmentsNovember 13, 2023 | finance.yahoo.comCORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and PlanNovember 11, 2023 | finance.yahoo.comOrganovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)November 8, 2023 | finance.yahoo.comOrganovo Highlights FXR314 Combination Therapy Potential and PlanNovember 7, 2023 | msn.comONVO, FATH and BYU among mid-day moversNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.October 10, 2023 | finance.yahoo.comONVO: A Company With Great Technology to Impact Health CareSeptember 8, 2023 | finance.yahoo.comOrganovo to Participate in the H.C. Wainwright Global Investment ConferenceAugust 25, 2023 | finance.yahoo.comIs Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapAugust 23, 2023 | finance.yahoo.comOrganovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 DataAugust 16, 2023 | msn.comOnvo receives $3 million grant from PennDOT to enhance electric vehicle charging infrastructureJuly 29, 2023 | seekingalpha.comONVO Organovo Holdings, Inc.July 20, 2023 | msn.comOnvo introduces first public fast electric vehicle chargers on I-81 stretchJune 7, 2023 | fool.comOrganovo (NASDAQ: ONVO)March 21, 2023 | finance.yahoo.comOrganovo Announces FXR ProgramFebruary 10, 2023 | finance.yahoo.comWill Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely?October 25, 2022 | finance.yahoo.comOrganovo Holdings, Inc. (ONVO)October 17, 2022 | finance.yahoo.comTrends in 3D-Printing Materials Technology and the Global Market for the Most Promising New 3D-Printing Materials Applications - Yahoo FinanceOctober 12, 2022 | benzinga.comHuman Liver Models Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | D - BenzingaOctober 9, 2022 | globenewswire.com3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market - GlobeNewswireOctober 3, 2022 | seekingalpha.comARKG: Too Hard To Pin Down, Too Volatile For Comfort (BATS:ARKG) - Seeking AlphaSeptember 30, 2022 | prnewswire.comGlobal Laboratory Animal Models, 3D Cultures and Organoids Markets, 2019-2021 & 2022-2027 - Opportunities in Organoids in Drug Development, Personalized Medicine and Transplantational Medicine - PR NewswireSeptember 30, 2022 | businesswire.comGlobal Human Liver Model Market Report 2022: Emerging 3D and 2D Trends in Modeling Human Liver Disease in Vitro Fuel Growth - ResearchAndMarkets.com - Business WireSeptember 29, 2022 | businesswire.com3D Bioprinting Global Market Report 2022: Long-term Forecasts to 2026 & 2031 Featuring Organovo Holdings, Allevi, Cellink, Aspect Biosystems, & 3D Systems - ResearchAndMarkets.com - Business WireSee More Headlines Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2019Today11/28/2023Next Earnings (Estimated)2/08/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONVO CUSIPN/A CIK1497253 Webwww.organovo.com Phone(858) 224-1000FaxN/AEmployees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,260,000.00 Net Margins-4,061.12% Pretax Margin-5,093.21% Return on Equity-129.61% Return on Assets-105.15% Debt Debt-to-Equity RatioN/A Current Ratio5.18 Quick Ratio5.18 Sales & Book Value Annual Sales$368,000.00 Price / Sales27.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book0.67Miscellaneous Outstanding Shares8,720,000Free Float8,284,000Market Cap$10.29 million OptionableOptionable Beta0.84 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Keith E. Murphy (Age 51)Company Secretary & Executive Chairman Comp: $626.24kMs. Vaidehi Joshi (Age 36)Director of Discovery Biology & Director Comp: $91.4kMr. Thomas P. Hess CPA (Age 59)MBA, President & CFO Dr. Curtis M. Tyree Ph.D.Senior Vice President of Strategy & Business DevelopmentKey CompetitorsAcorda TherapeuticsNASDAQ:ACORSurrozenNASDAQ:SRZNProtara TherapeuticsNASDAQ:TARABioCardiaNASDAQ:BCDAGenetic TechnologiesNASDAQ:GENEView All CompetitorsInsidersDavid GobelSold 19,607 sharesTotal: $31,763.34 ($1.62/share)View All Insider Transactions ONVO Stock Analysis - Frequently Asked Questions How have ONVO shares performed in 2023? Organovo's stock was trading at $1.41 at the beginning of the year. Since then, ONVO stock has decreased by 16.3% and is now trading at $1.18. View the best growth stocks for 2023 here. When is Organovo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our ONVO earnings forecast. How were Organovo's earnings last quarter? Organovo Holdings, Inc. (NASDAQ:ONVO) announced its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) EPS for the quarter, hitting the consensus estimate of ($1.00). The medical research company earned $0.67 million during the quarter, compared to the consensus estimate of $0.77 million. Organovo had a negative trailing twelve-month return on equity of 129.61% and a negative net margin of 4,061.12%. When did Organovo's stock split? Organovo shares reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Taylor Crouch's approval rating as Organovo's CEO? 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK). Who are Organovo's major shareholders? Organovo's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Gobel and Douglas Jay Cohen. View institutional ownership trends. How do I buy shares of Organovo? Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ONVO) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.